Xalkori 250 mg Alternative – Alkriz (Crizotinib) 250 mg Tablet | Beacon Pharmaceuticals
Alkriz 250 mg (Crizotinib) Tablet by Beacon Pharmaceuticals. Reference brand: Xalkori. ALK/ROS1 kinase inhibitor; used in molecularly selected non-small cell lung cancer. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
Alkriz 250 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Crizotinib. Xalkori is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
Alkriz vs Xalkori – Reference Brand Comparison
Xalkori is a recognized reference brand associated with Crizotinib. Alkriz is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: Alkriz. Active ingredient: Crizotinib. Strength: 250 mg. Dosage form: Tablet. Therapeutic class: ALK/ROS1 kinase inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Crizotinib is used in molecularly selected non-small cell lung cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Crizotinib Works
Crizotinib inhibits ALK and ROS1 signaling. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 250 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Crizotinib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include liver toxicity, vision changes, cardiac rhythm effects and lung inflammation. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include liver toxicity, vision changes, cardiac rhythm effects and lung inflammation. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is Alkriz Listed as an Alternative to Xalkori?
The comparison helps identify another listed brand containing Crizotinib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: Alkriz. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Xalkori. Generic: Crizotinib. Strength: 250 mg. Dosage form: Tablet.
Frequently Asked Questions
What is Alkriz 250 mg? It is a tablet containing Crizotinib 250 mg according to the supplied Beacon price list. What is it used for? Crizotinib is used in molecularly selected non-small cell lung cancer, subject to specialist assessment. Can it replace Xalkori? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Crizotinib |
|---|---|
| Strength | 250 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Gilotrif 40 mg Alternative – Afatin (Afatinib) 40 mg Tablet | Beacon Pharmaceuticals
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Ositag (Osimertinib) 80 mg Tablet | Beacon Pharmaceuticals
Tarceva 100 mg Alternative – Erlonix (Erlotinib) 100 mg Tablet | Beacon Pharmaceuticals
Tarceva 150 mg Alternative – Erlocent (Erlotinib) 150 mg Tablet | Incepta Pharmaceuticals
Erlocent 150 mg (Erlotinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tarceva (Roche / Genentech).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Tarceva 150 mg Alternative – Erlonix (Erlotinib) 150 mg Tablet | Beacon Pharmaceuticals
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xalkori 250 mg Alternative – Crizocent (Crizotinib) 250 mg Capsule | Incepta Pharmaceuticals
Crizocent 250 mg (Crizotinib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Xalkori (Pfizer).
Pack: 12 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Reviews
There are no reviews yet.